checkAd

     147  0 Kommentare Summit Appoints Robert W. Duggan as Chief Executive Officer - Seite 2

    Contacts

    Robert W. Duggan bob.duggan@summitplc.com  
    Summit Press Office investors@summitplc.com  

    Summit Forward-looking Statements

    Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company’s product candidates, the therapeutic potential of the Company’s product candidates, the potential commercialisation of the Company’s product candidates, the sufficiency of the Company’s cash resources, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that the Company makes with the Securities and Exchange Commission, including the Company’s Annual Report on Form 20-F for the fiscal year ended 31 January 2019. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

    Seite 2 von 3




    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Summit Appoints Robert W. Duggan as Chief Executive Officer - Seite 2 Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Appoints Robert W. Duggan as Chief Executive Officer Oxford, UK, and Cambridge, MA, US, 14 April 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today announces that Mr Robert (Bob) …